Table 4 IC50 of the 8 AJO14-derived compounds in different cell lines.
From: Development of an efficient NUPR1 inhibitor with anticancer activity
Cancer cell lines | IC50 value (μM) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
AJO14 | ED25 | ED28 | ED36 | ED61 | LZX-2-35 | LZX-2-56 | LZX-2-67 | LZX-2-73 | |
PDAC021T | 5.5 | 3.5 | 3.3 | 3.9 | 5.4 | 3.9 | 6.8 | 5.9 | |
PDAC056T | 14.5 | 4.3 | 3.2 | 3.7 | 1.9 | 5.3 | 2.9 | 9.1 | 3.4 |
PDAC074T | 20.2 | 9.2 | 3.8 | 3.9 | 3.7 | 5.7 | 5.9 | 4.9 | 5.7 |
PDAC079T | 14.4 | 6.1 | 5.7 | 2.3 | 3.5 | 3.2 | 2.6 | 2.7 | 3.1 |
PDAC087T | 10.6 | 17.5 | 24.9 | 15.6 | 16.8 | 12.7 | 12.6 | 10.3 | 13.6 |
PDAC088T | 11.2 | 5.7 | 5.7 | 4.2 | 3.8 | 5.6 | 3.5 | 4.3 | 4.2 |
PDAC091T | 20.2 | 13.9 | 14.8 | 14.4 | 17.8 | 19.3 | 17.4 | 16.4 | |
PDAC119T | 22.4 | 10.9 | 6 | 5.1 | 6.1 | 8.5 | 4.4 | 5.4 | 5.1 |
PC3 | 22.0 | 12.0 | 12.0 | 13.1 | 10.0 | 11.4 | 11.5 | 10.6 | 11.6 |
HT29 | 17.0 | 8.9 | 5.5 | 6.7 | 5.5 | 10.5 | 14.8 | 9.6 | 9.7 |
H358 | 20.2 | 17.0 | 18.4 | 14.8 | 15.9 | 14.9 | 19.1 | 11.8 | 12.0 |
A375 | 18.0 | 8.2 | 8.3 | 9.0 | 5.7 | 14.0 | 9.2 | 14.3 | 9.7 |
U87 | 14.0 | 13.6 | 13.4 | 12.8 | 14.9 | 11.3 | 8.5 | 9.9 | 11.1 |
MDA-MB-231 | 19.0 | 11.3 | 13.6 | 10.1 | 11.1 | 10.2 | 13.9 | 9.4 | 9.6 |
HepG2 | 10.3 | 5.7 | 6.5 | 7.7 | 5.8 | 10.1 | 5.6 | 8.9 | 5.6 |
U2OS | 13.0 | 10.5 | 14.4 | 12.5 | 10.4 | 16.2 | 10.0 | 14.4 | 10.0 |
